Alessandro Isidori

Ospedali Riuniti Marche Nord — Italy

Medicine · Health Sciences

36h-index4.7kcitations237works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(80), Chronic Myeloid Leukemia Treatments(68), Myeloproliferative Neoplasms: Diagnosis and Treatment(52), Chronic Lymphocytic Leukemia Research(50), Eosinophilic Disorders and Syndromes(31)

Publications234 total

Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
Cancer·2026Open Access
Fitness in CLL
Cancers·2026Open Access
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Blood Advances·2025Open Access
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
Blood Cancer Journal·2025Open Access
Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial
Blood·2025Open Access
Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study
Blood·2025
Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT
Blood·2025Open Access
CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with  myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study
Blood·2025Open Access
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia
Blood Cancer Journal·2025· 1 citedOpen Access
Real World Study on the Best <scp>CPX</scp> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
American Journal of Hematology·2025· 3 citedOpen Access
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib
Cancer·2025· 5 citedOpen Access
The role of menin inhibitors in acute myeloid leukemia
Current Opinion in Oncology·2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Leukemia Research·2025· 2 citedOpen Access
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Annals of Hematology·2025· 2 citedOpen Access
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
SSRN Electronic Journal·2025Open Access
Wiltse approach and inter-apophisary fusion for adolescent idiopathic scoliosis: Analysis of complications at the 2-year follow-up
Brain and Spine·2025Open Access
Radiation exposure in posterior fusion for adolescent idiopathic scoliosis: A comparison between low-dose, 2D fluoroscopy, navigation on preoperative CT scan and navigation on intraoperative CT scan
Brain and Spine·2025Open Access
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
Blood·2024· 2 cited
Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis
Blood·2024Open Access
page 1 of 12Next →

Frequent Co-authors

Giuseppe Visani(27), Roberto M. Lemoli(15), Michele Baccarani(13), Antonio Curti(12), Giovanni Martinelli(12), Pier Paolo Piccaluga(12), Massimo Breccia(12), Elisabetta Abruzzese(12), Mario Tiribelli(11), Monica Crugnola(11), Gianni Binotto(11), Roberto Latagliata(11), Michèle Cavo(11), Massimiliano Bonifacio(10), Alessandra Iurlo(10), Federica Loscocco(10), Francesco Cavazzini(9), Bruno Martino(9), Antonio Cuneo(9), Giuseppe A. Palumbo(9)